Ascletis Pharma Initiates U.S. Clinical Study Combining ASC47 and Semaglutide for Obesity Treatment

Reuters

05-20

Ascletis Pharma Initiates U.S. Clinical Study Combining ASC47 and Semaglutide for Obesity Treatment

HONG KONG, May 20, 2025/PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) has announced the commencement of a new clinical study, the ASC47-103 study, in the United States. The study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and preliminary efficacy of a single-dose, ultra-long-acting subcutaneous administration of ASC47 in combination with semaglutide for the treatment of obesity in participants without Type 2 diabetes. The ASC47-103 study involves three cohorts receiving single ascending doses of ASC47 (10 mg, 30 mg, and 60 mg) or a volume-matched placebo, alongside four weekly doses of semaglutide (0.5 mg). This marks the first clinical study combining a THRβ agonist and an incretin drug for obesity. Topline results from the study are anticipated in the fourth quarter of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN92026) on May 20, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2536613395"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536613395\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2536613395?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-20 18:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536613395","market":"nz","top_or_hot":-1,"title":"Ascletis Pharma Initiates U.S. Clinical Study Combining ASC47 and Semaglutide for Obesity Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ascletis Pharma Initiates U.S. Clinical Study Combining ASC47 and Semaglutide for Obesity Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HONG KONG, May 20, 2025/PRNewswire/ -- <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma Inc.</a> (HKEX:1672) has announced the commencement of a new clinical study, the ASC47-103 study, in the United States. The study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and preliminary efficacy of a single-dose, ultra-long-acting subcutaneous administration of ASC47 in combination with semaglutide for the treatment of obesity in participants without Type 2 diabetes. The ASC47-103 study involves three cohorts receiving single ascending doses of ASC47 (10 mg, 30 mg, and 60 mg) or a volume-matched placebo, alongside four weekly doses of semaglutide (0.5 mg). This marks the first clinical study combining a THRβ agonist and an incretin drug for obesity. Topline results from the study are anticipated in the fourth quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN92026) on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Pharma Initiates U.S. Clinical Study Combining ASC47 and Semaglutide for Obesity Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Pharma Initiates U.S. Clinical Study Combining ASC47 and Semaglutide for Obesity Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-20 18:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ascletis Pharma Initiates U.S. Clinical Study Combining ASC47 and Semaglutide for Obesity Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HONG KONG, May 20, 2025/PRNewswire/ -- <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma Inc.</a> (HKEX:1672) has announced the commencement of a new clinical study, the ASC47-103 study, in the United States. The study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and preliminary efficacy of a single-dose, ultra-long-acting subcutaneous administration of ASC47 in combination with semaglutide for the treatment of obesity in participants without Type 2 diabetes. The ASC47-103 study involves three cohorts receiving single ascending doses of ASC47 (10 mg, 30 mg, and 60 mg) or a volume-matched placebo, alongside four weekly doses of semaglutide (0.5 mg). This marks the first clinical study combining a THRβ agonist and an incretin drug for obesity. Topline results from the study are anticipated in the fourth quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN92026) on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDL1LtT0d:1","article_id":"2536613395","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536613395","pubTimestamp":1747735273,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HONG KONG, May 20, 2025/PRNewswire/ -- Ascletis Pharma Inc.  has announced the commencement of a new clinical study, the ASC47-103 study, in the United States. The study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and preliminary efficacy of a single-dose, ultra-long-acting subcutaneous administration of ASC47 in combination with semaglutide for the treatment of obesity in participants without Type 2 diabetes. The ASC47-103 study involves three cohorts receiving single ascending doses of ASC47  or a volume-matched placebo, alongside four weekly doses of semaglutide . This marks the first clinical study combining a THRβ agonist and an incretin drug for obesity. Topline results from the study are anticipated in the fourth quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","01672":"歌礼制药-B"},"translate_title":"歌礼制药启动ASC47与索马鲁肽联合治疗肥胖的美国临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":0.9},"content_text":"Ascletis Pharma Initiates U.S. Clinical Study Combining ASC47 and Semaglutide for Obesity Treatment\n    \n\n        HONG KONG, May 20, 2025/PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) has announced the commencement of a new clinical study, the ASC47-103 study, in the United States. The study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and preliminary efficacy of a single-dose, ultra-long-acting subcutaneous administration of ASC47 in combination with semaglutide for the treatment of obesity in participants without Type 2 diabetes. The ASC47-103 study involves three cohorts receiving single ascending doses of ASC47 (10 mg, 30 mg, and 60 mg) or a volume-matched placebo, alongside four weekly doses of semaglutide (0.5 mg). This marks the first clinical study combining a THRβ agonist and an incretin drug for obesity. Topline results from the study are anticipated in the fourth quarter of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN92026) on May 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}